John Overdeck’s Marker Therapeutics MRKR Stock Holding History

John Overdeck’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88.5K	Sell	60,201 -800	-1%	-$1.17K	﹤0.01%	4907
2026 Q1	$79.3K	Sell	61,001 -37,140	-38%	-$58.9K	﹤0.01%	4413
2025 Q4	$146K	Buy	98,141 +61,601	+169%	+$69.8K	﹤0.01%	3809
2025 Q3	$32.6K	Buy	+36,540	New	+$45.1K	﹤0.01%	3565
2023 Q1	–	Sell	-1,590	Closed	-$4.23K	–	3113
2022 Q4	$4.23K	Sell	1,590 -3,805	-71%	-$13.1K	﹤0.01%	2753
2022 Q3	$20K	Sell	5,395 -12,122	-69%	-$44.5K	﹤0.01%	2381
2022 Q2	$58K	Sell	17,517 -8,055	-31%	-$26.8K	﹤0.01%	2332
2022 Q1	$113K	Sell	25,572 -32,838	-56%	-$188K	﹤0.01%	2419
2021 Q4	$555K	Sell	58,410 -30,291	-34%	-$402K	﹤0.01%	3142
2021 Q3	$1.5M	Sell	88,701 -11,332	-11%	-$232K	﹤0.01%	2242
2021 Q2	$2.79M	Buy	100,033 +89,113	+816%	+$2.35M	0.01%	1601
2021 Q1	$245K	Buy	+10,920	New	+$250K	﹤0.01%	3491

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

John Overdeck's MRKR Position: Q2 2026 in Review

John Overdeck reduced its Marker Therapeutics (MRKR) stake by 1.3% in Q2 2026, selling an estimated $1.17K and leaving 60,201 shares worth $88.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4907.

John Overdeck first reported a position in MRKR in Q1 2021 and has held it in 12 quarters since. The position peaked at $2.79M in Q2 2021. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

John Overdeck held 60,201 shares of Marker Therapeutics worth $88.5K as of Q2 2026.
John Overdeck sold 800 Marker Therapeutics shares in Q2 2026, an estimated $1.17K.
Marker Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4907 holding.
John Overdeck first reported a position in Marker Therapeutics in Q1 2021 and has held it in 12 quarters since.
John Overdeck's Marker Therapeutics position peaked at $2.79M in Q2 2021.
35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.